News Release

The Myelin Repair Foundation and Teva Pharmaceutical Industries Collaborate on Neuro-protection and Myelin Repair for the Treatment of Multiple Sclerosis

Sunnyvale, CA—October 20, 2015—The Myelin Repair Foundation (MRF) entered an agreement with Teva Pharmaceutical Industries to evaluate technologies developed at the MRF’s Translational Medicine Center (TMC) to advance the development of therapeutics for Multiple Sclerosis (MS). The MRF has recently experienced a challenging financial position and made the difficult decision to close their Translational Medicine Center. Teva has agreed to support the MRF TMC and enable the non-exclusive transfer of knowledge related to myelin repair and protection into Teva’s research teams.

MRF’s TMC has developed a portfolio of assays designed to identify and evaluate potential therapeutics for their ability to stimulate, protect and repair myelin. These assays combine the sophistication and eloquence available in state of the art academic laboratories, with the rigor and reproducibility that the pharmaceutical industry needs for drug discovery.

Myelin is the fatty material that protects nerves and is damaged in Multiple Sclerosis. Repairing myelin could benefit patients with MS, including progressive forms, for which there are currently no approved treatments.

“We are happy to collaborate with the MRF for a period of time so that Teva can protect the unique contributions the MRF has made to the field of neuro-protection.” said Michael Hayden, MD, PhD, President of Global R&D and Chief Scientific Officer at Teva. “We look forward to working with the dedicated MRF team and continuing work on myelin repair.”

“This collaboration reflects Teva’s commitment and leadership to develop innovative therapeutics for MS patients. The MRF is delighted that Teva recognizes the value of the assays developed and the drug screens performed at our Translational Medicine Center. We are enthusiastic about working with Teva’s experts so they can evaluate the TMC technologies for their use in the developing new medicines for MS. Development of therapeutics to protect and repair myelin has always been the mission of our foundation, and working with Teva will ensure that the technologies developed by the MRF’s TMC will continue to be used for this purpose.” said Jay S. Tung, PhD, Chief Research Officer at MRF.

About the Myelin Repair Foundation; The Myelin Repair Foundation (MRF) (www.myelinrepair.org) is a Silicon Valley-based, non-profit research organization focused on accelerating the discovery and development of myelin repair therapeutics for Multiple Sclerosis.

About Teva Pharmaceutical Industries Ltd. (NYSE and TASE); Teva is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions to millions of patients every day. Headquartered in Israel, Teva is the world’s largest generic medicines producer. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including Multiple Sclerosis. www.tevapharm.com

Contact for Inquiries:

Scott Johnson, President, CEO and Founder
The Myelin Repair Foundation
scott@myelinrepair.org
408-871-2410

Jay S. Tung, Ph.D., Chief Research Officer
The Myelin Repair Foundation
jay@myelinrepair.org
408-871-2410